
Meditate For Brain Health: AI Research & Science Promote This Solution
Digital human brain with connections.
It's not hard to find science showing that chronic stress can be hard on the brain.
We know intuitively that stress can be harmful to our bodies, and even though it's a natural part of life, excessive stress is to be avoided. To be sure, there are different kinds of stress. There's the kind that propels you forward to finish a project, that, if handled correctly, can be fine. Then there's the kind of stress that puts too much pressure on the cardiovascular system and, ultimately, the brain too, that you might describe as 'eating away' at you – chronic or episodic stress.
New science suggests that inappropriate stress responses can rewire the brain, and that decreasing stress can have a very positive effect on cognition.
Here's a piece from the University of Alabama at Birmingham that talks about the difference between chronic stress and common short-term stress activity
'The key differences between 'normal' stress and chronic stress lie in duration and intensity,' writes Teresa Hicks. 'Acute stress is typically short-term, triggered by a specific event or situation. It causes a temporary reaction that subsides once the stressor is resolved, allowing the body to recover and return to a balanced state. Chronic stress arises when a persistent stressor lingers for an extended period with few opportunities for resolution.'
The recommendations from experts are often the same – eat a good diet, maintain fitness, and sleep well, also enjoying fun and relaxing activities.
And then there's meditation.
Brian - neuroinflammation
Balachundhar Subramaniam is a professor of anesthesiology who has done research on the role of meditation in combating conditions like brain fog, which can cause forgetfulness and make it hard to concentrate.
Subramaniam started the Sadhguru Center for a Conscious Planet to expand our understanding of Consciousness, Cognition, and Compassion.
In a presentation, he shows how the experience of life improves with regular meditation and lower stress levels in general, starting with an explanation of what we face.
'There is this slow fire that is burning in your brain,' he said. 'It's not large enough to recognize, but surely and slowly, (it's) burning down your neurons and the supporting structure, and accelerating your mental thoughts and your fear, your anxiety, your stress, and also the aging process.'
He called this 'neuro-inflammation.'
'It can accelerate memory loss,' he said. 'It can worsen your anxiety, it can worsen your stress, and above all, it can be facilitating dementia. It's important to note, not just that, what you eat … can add fuel to this fire. If you don't have a good night, restorative sleep, it also adds fuel to the fire. And (if you are) deprived of joy, that also adds fuel to the fire of this slow decline that is inflammation.'
Blood Proteins
Subramaniam went over some of the history of this research through the pandemic years, which were uniquely stressful for most of us.
'We looked at 5000 people who were doing this meditation at the time of the pandemic,' he said. 'Even before the vaccine was announced, they were practicing it five days a week, for at least six months or longer, and (we) compared it to 2500 people from similar zip codes, and of the same age group and gender mix.'
What did they find?
'They had the lowest levels of stress, not just once, but repeated after four weeks and another four weeks, so three time points, even before the vaccine was announced,' he added. 'So they were not just surviving, but really thriving.'
Subramaniam talked about looking at reactive proteins, and presented a graph with results for surveyed patients with severe Covid.
'Meditation can cool the fire of neuroinflammation,' he said. 'We are actually in a position to fight against infection … maybe when the next pandemic comes.'
Pandemic Stress
There's also additional research on relevant topics, where you can see more about the role of stress on the body.
For example, a landmark study on stressed caregivers suggests that daily Kirtan Kriya yoga meditation, according to the authors, 'down-regulated pro-inflammatory gene expression.'
The upshot of it?
'Compared to a relaxation-control group, meditators had reduced transcription of cytokine genes and lower activity of the pro-inflammatory NF-κB pathway in their immune cells.'
And there's more on brain aging and neuroplasticity.
Many of these pieces of research help to paint a better picture of how we improve our neurology, including with anti-stress practices.
Subramaniam also talked about the recent designation of the gut as the 'second brain,' and the ways that the microbiome works with our cognition.
Identifying higher levels of healthy lactobacillus in the guts of people engaging in good anti-stress behaviors. He noted that the secondary effect can be good, too.
Subramaniam mentioned situations where you experience your mind wandering – a lot.
'How many of you have been having that problem? Your mind always wanders. Something is happening in the back of your brain all the time. Right at the front of the brain, you have a switch center … and in these people, at baseline, the connection between the switch and the mind wandering center is enhanced after meditation. So you can actually switch it between the two, whether you're going to do the task, or whether you're going to go to the mind wandering states.'
Meditation, he said, helps you get control of your brain, not wrangling with what he called a 'monkey brain,' but being adaptive and capable in key ways.
Specifically, Subramaniam recommends a practice called shoonya meditation. (read about it here.)
Neuroinflammation and Measurability
In aid of explaining this further, Subramaniam revealed something he calls the 'brain age index,' and showed how after a retreat, people were feeling better due to interactions with endocannabinoids and what he called the 'bliss molecule.'
You might ask: what is the relevance of AI here?
Before we learned to aggregate data, crunch it, and reveal insights, in an automated way, a lot of this kind of research was simply not possible.
I've written about various types of research that bring AI to neuroscience, to put the human brain under a microscope. There's the synergistic idea that as we learn about our brains, we learn to better understand the work of neural nets, and vice versa. That's why I am including this blog post here.
Another compelling part of the talk involved Subramaniam showing a line of the conjunction between awareness, and life experience, again showcasing some of the science of gaining better neurological control.
'This is a gift to be born as a human,' he said, exhorting us to think about life hacks that will improve our experiences. 'Time is short.'
The bottom line is that meditative techniques may be able to help us to live better and ward off cognitive problems later in life. Think about it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
14 minutes ago
- Bloomberg
NASA Considers Launching Astronaut Mission Next Week After Delay
NASA is considering launching its fourth astronaut mission to the International Space Station as early as next Thursday after a repair review caused a delay. NASA has looked into repair efforts for what it described as small leaks in a service module at the ISS. NASA, Axiom Space, and Elon Musk's SpaceX are now reviewing launch opportunities as soon as June 19, it said in a statement.


Forbes
14 minutes ago
- Forbes
Burnout Or Biology? Metabolic Health Drives Entrepreneur Success
BEVERLY HILLS, CA - OCTOBER 28: Emilia Clarke (Right) and Sharon Waxman, TheWrap's CEO and ... More Editor-in-Chief (Photo byfor TheWrap) The world's most forward-thinking founders aren't just measuring revenue or user acquisition; they're monitoring metabolic performance. Tools like continuous glucose monitors (CGMs), mitochondrial assessments and circadian rhythm trackers are fast becoming C-suite essentials. The reason? Burnout is no longer a productivity tax that needs to be normalized. It's a biological signal that something deeper is off. Within our current volatile entrepreneurial landscape, a new paradigm is emerging, one that treats metabolic health not as a wellness fad but as a strategic performance metric. At its core, this shift reframes bioenergetics as leadership currency: a founder's ability to perform under pressure, think clearly and lead with emotional resilience is directly tied to cellular efficiency. Metabolic health refers to the body's ability to regulate glucose, insulin, lipids, inflammation and energy production effectively. Unlike conventional health goals centered on weight or appearance, metabolic optimization focuses on internal function. Enter: hormonal balance, mitochondrial resilience, metabolic flexibility, or the ability to switch efficiently between fuel sources. This flexibility allows leaders to sustain focus without crashing, reduce their dependency on caffeine or sugar and recover from stress with greater ease. As neuroscience increasingly shows, stable metabolism supports executive function by aligning brain and gut rhythms, both crucial for strategic decision-making. It comes as no surprise, then, that disrupted rhythms from poor sleep, chronic stress and erratic eating silently sabotage performance. What looks like a mindset issue (brain fog, emotional reactivity, impulsivity) is often a mitochondrial issue in disguise. Glucose is the brain's preferred fuel, especially the prefrontal cortex, which governs decision-making, foresight and emotional regulation. Fluctuations in blood sugar can trigger mood volatility and mental fatigue, mimicking burnout. When metabolic dysfunction becomes chronic, cognitive capital deteriorates. Research suggests that workplace interventions targeting metabolic health can reduce perceived stress, prevent burnout and boost self-efficacy. For high-stakes entrepreneurs, this translates into sharper focus, faster recovery and a more grounded, aligned leadership lifestyle. Founders are now embracing data-driven tools to optimize their biological systems. Popular devices and practices include: Executives at Levels Health, InsideTracker and other biohacking-forward VC firms are leading the charge, blending health optimization with high-performance strategy. Some companies are even incorporating mitochondrial health assessments and biological age tests into leadership retreats and C-suite onboarding. Jet lag, pitch decks, red-eye flights and late-night decision sprints take a toll. Entrepreneurial lifestyles often glorify the grind, but the biochemical impact is true to life: elevated cortisol, impaired glucose control and circadian disruption fuel chronic inflammation, eroding resilience from the inside out. A 2025 study found that stress-induced metabolic dysfunction in healthcare professionals mirrors patterns seen in tech executives: high output paired with poor recovery. Over time, this results in mitochondrial fatigue, hormone imbalances and emotional burnout, not because founders are undisciplined but because their internal systems are under siege. The good news? Metabolic health is highly modifiable and functional. Entrepreneurs are turning to science-backed interventions like: However, the most overlooked intervention is also the most essential: sleep. Without circadian balance, even the most sophisticated strategies won't yield results. Deep rest is the bedrock of sustained performance. Note: Always consult your primary care provider before initiating any new health interventions. The most effective leaders integrate biological metrics into their performance strategies. From glucose variability and heart rate variability to mitochondrial health and circadian alignment, internal data is fast becoming as critical as quarterly reports. Metabolically optimized leaders demonstrate improved cognitive function, emotional regulation and decision-making capacity: key traits backed by neuroscience and performance psychology. Emerging organizational models reflect this shift, with VC firms and executive teams investing in biologically intelligent infrastructure: continuous monitoring tools, resilience protocols and recovery-based culture design. Burnout is no longer a vague emotional state but a measurable physiological response driven by chronic inflammation, insulin resistance and cellular fatigue. And treating it goes beyond rest. It requires recalibration at the metabolic level, the epitome of every leader's imperative. The next KPI isn't visible on a spreadsheet. It's encoded in your biology. Optimize it, and you'll gain not just longevity but a strategic edge.


Health Line
43 minutes ago
- Health Line
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration reportedly plans to cut almost all funding for HIV vaccine research. Experts say the decision comes at a time when research in this field is making substantial progress. Many effective treatments are available for HIV, but these are lifelong commitments that manage a chronic disease rather than cure it. Treatments for HIV infection have come a long way since the 1980s, when too many lives were lost during the epidemic. Today, antiretroviral therapies and other treatments allow people with HIV to live longer lives and, in many cases, prevent the transmission of the virus that causes the disease to other people. Scientists now say the next step in the fight is a vaccine that protects against HIV. However, that next development could be on the chopping block. Trump administration officials reportedly plan to halt funding for a wide array of HIV vaccine research. Researchers told CBS News they have been informed by officials at the National Institutes of Health (NIH) that the Department of Health and Human Services (HHS) has instructed the agency not to issue any more funding during the next fiscal year for HIV vaccine research. NIH officials said HHS officials have instead decided to 'go with currently available approaches to eliminate HIV.' The decision will close down HIV vaccine research projects at the Duke Human Vaccine Institute and the Scripps Research Institute, according to a report in the journal Science. Officials at Moderna also told CBS News that their current clinical trials on HIV vaccines have been put on hold. Experts say the decision to cut funding for an HIV vaccine is short-sighted and reckless. 'I'm stunned by this decision,' said Jake Scott, MD, a clinical associate professor of medicine at Stanford University in California who specializes in infectious diseases. 'There is no scientific or medical evidence to justify these cuts at the exact moment this field is showing real promise,' he told Healthline. Carl Baloney Jr., the chief executive officer-elect of AIDS United, agreed. 'Eliminating funding for HIV vaccine research undermines decades of scientific progress and turns our back on a future where HIV could be preventable for all, regardless of where someone lives, their income, or access to healthcare,' he told Healthline. Why an HIV vaccine is important Experts say that treatments for HIV are incredibly effective. However, they note that most involve daily adherence and aren't necessarily readily available or affordable for many people. 'There are a lot of good options, but they can be really expensive,' Scott said. 'These medications are also not a cure. They are a lifetime burden.' The experts add that people with low levels of HIV in their system can still have weakened immune systems. That can raise the risk of serious infections as well as inflammation that can lead to conditions such as heart disease. 'A vaccine can help prevent all this,' said Scott. Experts note that a vaccine research program may be difficult to put back together even if a new administration restored funding in the near future. They say it took decades to build these programs and restarting them would take time. In addition, researchers will leave the field of HIV prevention to set up shop in another industry that is receiving funding. 'We could lose an entire generation of scientists,' said Scott. 'This is setting the field back a decade or more at a critical time.' 'This isn't just about canceling [a] clinical trial. It's about sidelining the scientists, institutions, and community partners driving innovation forward,' added Baloney. 'These setbacks could delay the development of a successful HIV vaccine by years or even decades.' How scientists fought against HIV The first treatment for HIV was approved by the Food and Drug Administration (FDA) in 1987. Azidothymidine (AZT) was first developed in 1964 as a treatment for cancer. It was ineffective in that usage, but in the 1980s, scientists discovered AZT could suppress HIV replication without damaging healthy cells. It helped treat people with AIDS as well as people who were HIV positive but had no symptoms. In the 1990s, other nucleoside reverse transcriptase inhibitors (NRTIs) were developed and approved. Laboratory tests to measure viral load and cell counts accelerated this research. From there, scientists experimented with combining drugs to help counter the HIV virus's ability to mutate and replicate. In 1996, a triple-drug therapy proved effective in thwarting HIV replication and creating a barrier against drug resistance. Since then, these antiretroviral drugs have become more effective and more available. The effectiveness of these medications is nothing short of miraculous. In the 1980s, the average life expectancy after an AIDS diagnosis was one year. Today, people who adhere to combination antiretroviral drug therapies can expect to live a near-normal life span. In some cases, the medications can reduce the HIV viral load in a person to the point where the virus is undetectable and can't be transmitted to another person. How is HIV treated today? More than 50 types of HIV medications are now approved for use. Some of the more commonly used antiretroviral medications are: Combination NRTI drugs that include Truvada and Descovy. These medications work by preventing HIV from converting its RNA into DNA. This prevents the virus from making copies of itself.. Integrase strand transfer inhibitors (INSTIs) that include Vocabria and Biktarvy. These drugs work by blocking an enzyme that HIV uses to put HIV DNA into human DNA inside cells. Protease inhibitors (PIs) such as Lexiva and Crixivan. These medications work by blocking an enzyme that HIV needs as part of its life cycle. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that include Intelence and Viramune. These drugs work by preventing the HIV virus from making copies of itself. Entry inhibitors such as Fuzeon and Selzentry. These medications work by blocking HIV from entering CD4 T cells. In addition, there are drugs known as Cytochrome P4503A (CYP3A) inhibitors, such as Tybost and Norvir, that help boost the levels of HIV medications in the bloodstream. There are also medications known as post-attachment inhibitors that when used with antiretroviral drugs can help prevent HIV from entering immune cells. Trogarzo was the first of these drugs to become available, having been approved in 2018. In addition, there are attachment inhibitor medications, a newer form of HIV drug that works by attaching to a viral protein, which prevents that protein from entering healthy T cells. Only one type of this medication, Rubokia, is currently available, having been approved in 2020. Most people with HIV are given medications, but there also are long-acting injections that are given once a month or once every other month. Scott said these treatments are cures that have turned HIV into a 'managed chronic disease' to the point where he and other colleagues now refer to AIDS as 'advanced HIV.' Baloney said, however, there are limits to how much treatments can do. 'Current treatments and prevention tools have transformed HIV into a manageable chronic condition, but they are not a cure and they're not accessible to everyone,' he said. 'An HIV vaccine would be a game-changer, especially for communities facing systemic barriers to care.' Preventive measures for HIV Even with the available treatments, experts agree that it's better for a person if they don't contract HIV in the first place. They say condom use, along with dental dams and gloves, can be effective barriers to contracting HIV. Limiting sexual partners is also recommended, as are sterile needles for intravenous drug users. Getting tested for HIV is also an important component. It's estimated that more than 1 million people in the United States have HIV, and 13% of them don't know they have contracted the virus. There are medications available that can be taken as a precaution or after potential exposure to HIV. These drugs include: Preexposure prophylaxis (PrEP): These medications can be taken as a daily pill or a bimonthly injection. The first injectable PrEP drug was Apretude, which was approved by the FDA in 2021. Truvada can also be used as PrEP therapy. These medications help prevent HIV from getting a foothold in the body. Postexposure prophylaxis (PEP) drugs: These are designed to be taken within 72 hours of potential exposure to HIV. It is a pill ingested once a day for 28 days. Lenacapavir: This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on June 19. Experts say all these preventive measures are good practices, but they note that vaccines are still the most effective.